CMMB Q3 2019 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$7M

EPS (Diluted)

$-15.56

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$15,987	+100.0%
Operating Income	-$7M	-$3M	-190.5%
Net Income	-$7M	-$3M	-172.4%